Bold claim: daily radiotherapy scans for prostate cancer could also steer how treatment is tweaked to reduce side effects, not just guide positioning. But here's where it gets controversial: the same imaging done to line up beams might reveal early signs of future rectal bleeding, potentially weeks before symptoms appear.
Researchers used artificial intelligence to analyze daily scans from 187 patients undergoing prostate radiotherapy. They looked for radiomic features—subtle texture and pattern details in the images—that correlate with later toxicity. Strikingly, patterns visible in a single scan as early as one week into treatment were highly predictive of rectal bleeding that could occur within two years after therapy. When they combined information from the first three weeks of scans, the predictions became even more reliable. This suggests that monitoring these imaging features could create an early window to intervene, personalizing and possibly reducing side effects without sacrificing cancer control.
The team emphasizes that this approach relies on better use of data already being collected, rather than requiring new technologies or extra scans. In practice, such predictive biomarkers could be integrated into routine planning and ongoing monitoring to decide when and how to adapt a patient’s radiotherapy plan.
However, the researchers caution that turning this concept into standard care will take time. A larger, confirmatory study and advances in automation would be needed before clinicians routinely alter treatment plans based on these early radiomic signals.
The study was funded by Prostate Cancer UK and involved collaborators from the University of Cambridge and The Christie NHS Foundation Trust. As Professor Bill Nailon notes, this work provides a proof-of-concept that imaging collected for beam setup can support adaptive workflows. Real-world adoption will require further trials and development before such approaches inform daily clinical decisions.
Experts from Prostate Cancer UK stress that while prostate radiotherapy is highly effective, the movement of the prostate and nearby organs can cause collateral damage, including bleeding. The goal is to make treatments gentler without compromising outcomes. Partnerships with Movember and the Garfield Weston Foundation helped fund this line of inquiry, underscoring a shared aim to tailor radiotherapy to individual patients. More research in larger groups is needed, but this represents a meaningful step toward kinder, more personalized radiotherapy for men who need it.
Source: University of Edinburgh
Date: 16 December 2025
Question for readers: Do you think leveraging existing scans for adaptive treatment is a practical next step, or would the required validation and automation slow down real-world implementation too much? Share your thoughts and any concerns about safety, equity, or access in the comments.
